Alnylam can develop global liver cancer RNAi on PhII data from China deal with Ascletis
This article was originally published in Scrip
Alnylam Pharmaceuticals lined up Ascletis Pharmaceuticals in China to develop ALN-VSP for liver cancers, including hepatocellular carcinoma (HCC). This is the first new partner for one of Alnylam's RNA interference programmes since the company announced a corporate restructuring that relied on collaborations to advance the company's RNAi therapeutics.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.